22 January 2018 - First presentation of bivalirudin in frozen, premixed, ready-to-use formulation.

Baxter International today announced the U.S. FDA approval of bivalirudin in 0.9% sodium chloride injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anti-coagulant in patients undergoing percutaneous coronary intervention, a common non-surgical procedure to treat blocked or narrowed blood vessels in the heart.

Bivalirudin will use Baxter’s proprietary frozen GALAXY container technology, a non-PVC and non-DEHP system specifically designed to create a ready-to-use format for unstable molecules. Pre-mixed versions of commonly prescribed drugs help simplify the preparation process and can avoid potential errors that may occur when medications are compounded. Compounding is the process of combining different ingredients in specific quantities to fill individualised prescriptions.

Read Baxter press release